Supplementary Data

A novel LRP1-binding peptide L57 that crosses the blood brain barrier

Kotaro Sakamoto, Tokuyuki Shinohara, Yusuke Adachi,

Taiji Asami, Tetsuya Ohtaki

Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited,
Fujisawa 251-8555, Japan

Contents



Fig. S1. Plasma stability of the synthetic peptide, L57. The remaining amount of peptide (%) in mouse plasma was measured at the indicated time points (0, 5, and 20 min). NMU8 (gray squares) is a linear octapeptide that was used as a control peptide.



Fig. S2. Brain uptake of Angiopep-2 and Angiopep-7 in mice. Brain uptake of ^{125}I-labeled peptides [Angiopep-2 (Ang-2), Angiopep-7 (Ang-7)] was evaluated by *in situ* brain perfusion in mice. Radioisotope counts in the right brain hemisphere were measured after 5 min of perfusion. Data are means + SDs (n = 3).

Table S1

Brain uptake of ^{125}I-labeled peptides in mice.

Name	Sequence	*In situ* brain perfusion (% input)
Angiopep-2	TFFYGGSRGKRNNFKTEEY-OH	0.035 ± 0.005
Angiopep-7	TFFYGGSRGRRNNFRTEEY-OH	0.062 ± 0.004

Data are means ± SDs (n = 3).